Drug Trial Radar · NCT00129181
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Aug 28, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 2005
Primary completion
Dec 2006
Study completion Jan 2007
Sponsor
- Lead sponsor
- Institute for Neurodegenerative DisordersAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer; GE Healthcare
- First posted
- Aug 11, 2005
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane (\[123I\]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
Conditions
- Parkinson Disease
- Parkinsonian Syndrome
Interventions
cabergolineDrug
Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
carbidopa/levodopaDrug
Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
DATscan and SPECT imagingProcedure
Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the influence of short-term levodopa therapy on dopamine transporter density in early Parkinson's diseaseTime frame: 1 year
Locations
9 sites in 4 countries. Site status is shown where the registry gives one.
Department of Neurology, Innsbruck Medical University
Innsbruck, Austria
Neurological Department, Wilhelminenspital
Vienna, Austria
Dept. of Neurology, University of Leipzig
Leipzig, Germany
Dept. of Neurology Marburg, Phillips-Univ.
Marburg, Germany
Ambulanz für Bewegungsstörungen, Neurologische Poliklinik
München, Germany
University of Catania-Department of Neurosciences
Catania, Italy
Parkinson Institute Milan
Milan, Italy
Department of Neurological Sciences-University of Napoli
Naples, Italy
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.